Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 0.78 |
| ▸ | HTR1D | P28221 | 20/20 | 0.78 |
| ▸ | HTR1B | P28222 | 20/20 | 0.78 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR1E | P28566 | 1/20 | 0.60 |
| ▸ | HTR1F | P30939 | 1/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | HTR5A | P47898 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6398194 | 0.88 | HTR1A (1.00) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL6393143 | 0.84 | HTR1A (0.73) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5212911 | 0.83 | HTR1A (0.76) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL6397811 | 0.83 | HTR1A (0.76) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL6398686 | 0.82 | HTR1A (1.00) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL6395407 | 0.82 | HTR1A (0.77) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL6393225 | 0.81 | HTR1A (1.00) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5210689 | 0.81 | HTR1A (0.83) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL6393656 | 0.81 | HTR1D (0.55) | HTR1AHTR1DHTR1BADRB2DRD2 | |
| SCHEMBL5213305 | 0.80 | HTR1A (0.78) | HTR1AHTR1DHTR1BADRB2DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | GLAXO GROUP LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1476161-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068236-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES POSSESSING AFFINITY AT 5HT-1 TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176724-A1 | Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors | HTR5A, HTR2C, HTR3C | HTR1A 4/4885HTR1D 9/4885HTR1B 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.